New perspectives on basic mechanisms in lung disease. 1. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis
- PMID: 1494772
- PMCID: PMC1021104
- DOI: 10.1136/thx.47.12.1064
New perspectives on basic mechanisms in lung disease. 1. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis
Abstract
It is over 25 years since Scadding first defined the term fibrosing alveolitis. It has since been established that complex mechanisms underlie its pathogenesis, including epithelial and endothelial injury, vascular leakage, production of inflammatory cells and their mediators, and fibroblast activation. Only through a detailed knowledge of how these cellular and molecular events are interlinked will we learn how to combat this disease, which is notoriously resistant to present treatments. So far the only therapeutic advances have been refinements in immunosuppression, and even these treatments are frequently disappointing. We believe that future advances in treatment will come from the development of agents that protect endothelial and epithelial cells from further injury and agents that can inhibit release of inflammatory mediators. A better knowledge of the mechanisms of collagen gene activation and the biochemical pathways of collagen production may also allow the identification of vulnerable sites at which new treatments may be directed. A combined approach to modifying appropriate parts of both the inflammatory component and the fibroblast/collagen component should provide a new stimulus to research. Further epidemiological studies are also needed to identify the environmental causes of lung injury that initiate the cascade of events leading to interstitial fibrosis.
Similar articles
-
Molecular mechanisms of pulmonary fibrosis and current treatment.Curr Mol Med. 2001 Nov;1(5):551-73. doi: 10.2174/1566524013363401. Curr Mol Med. 2001. PMID: 11899231 Review.
-
Idiopathic pulmonary fibrosis: cellular and molecular pathogenesis.Am J Med Sci. 1989 Feb;297(2):91-104. doi: 10.1097/00000441-198902000-00005. Am J Med Sci. 1989. PMID: 2919636
-
[Biopathology of fibrosing alveolitis].Rev Prat. 1991 May 11;41(14):1247-52. Rev Prat. 1991. PMID: 2068515 Review. French.
-
[Pathogenesis of idiopathic pulmonary fibrosis].Immun Infekt. 1995 Jun;23(3):92-6. Immun Infekt. 1995. PMID: 7615308 Review. German.
-
Effect of lung T lymphocytes on fibroblasts in idiopathic pulmonary fibrosis and extrinsic allergic alveolitis.Thorax. 1990 Jun;45(6):451-5. doi: 10.1136/thx.45.6.451. Thorax. 1990. PMID: 2392789 Free PMC article.
Cited by
-
Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.BMC Cancer. 2019 Feb 20;19(1):163. doi: 10.1186/s12885-019-5367-0. BMC Cancer. 2019. PMID: 30808322 Free PMC article.
-
New strategies for treatment of pulmonary fibrosis.Thorax. 1995 Apr;50(4):415-21. doi: 10.1136/thx.50.4.415. Thorax. 1995. PMID: 7785018 Free PMC article. Review. No abstract available.
-
Sputum hyaluronan and versican in severe eosinophilic asthma.Int Arch Allergy Immunol. 2013;161(1):65-73. doi: 10.1159/000343031. Epub 2012 Dec 14. Int Arch Allergy Immunol. 2013. PMID: 23257685 Free PMC article. Clinical Trial.
-
Localisation of a pulmonary autoantigen in cryptogenic fibrosing alveolitis.Thorax. 1994 Nov;49(11):1139-45. doi: 10.1136/thx.49.11.1139. Thorax. 1994. PMID: 7831631 Free PMC article.
-
Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts.Lung. 2005 Jul-Aug;183(4):225-37. doi: 10.1007/s00408-004-2534-z. Lung. 2005. PMID: 16211459 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical